{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:32Z","timestamp":1791472112732,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Celltrion, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Superior efficacy of subcutaneous infliximab (CT-P13 SC) over placebo for maintenance therapy in patients with Crohn\u2019s disease (CD) and ulcerative colitis (UC) was demonstrated in the randomized LIBERTY-CD and LIBERTY-UC studies. The current post hoc analysis compared outcomes with CT-P13 SC by baseline immunosuppressant use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderately to severely active CD or UC randomized to the CT-P13 SC maintenance arm of the 54-week LIBERTY trials at week 10 and who were treated in the open-label extension (weeks 56\u2013102) were included. Pharmacokinetic, efficacy, biomarker, safety, and immunogenicity endpoints were evaluated by baseline immunosuppressant use (monotherapy vs combination therapy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 192 patients with CD (monotherapy, n\u2005=\u2005126; combination therapy, n\u2005=\u200566) and 237 patients with UC (monotherapy, n\u2005=\u2005180; combination therapy, n\u2005=\u200557) were included. In both studies, efficacy outcomes were generally comparable between monotherapy and combination therapy at week 54 or week 102. Serum concentrations were generally higher, and antidrug antibody-positive conversion rates were lower, with combination therapy relative to monotherapy. In combined analyses of CD and UC, comparable safety profiles were observed between monotherapy and combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite some differences in pharmacokinetics and immunogenicity between CT-P13 SC received alone or in combination with immunosuppressants in patients with CD or UC, efficacy outcomes at week 54 or week 102 were generally comparable. The overall safety profile and incidence of systemic injection reactions were also comparable between monotherapy and combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf038","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T15:25:29Z","timestamp":1741274729000},"page":"2714-2724","source":"Crossref","is-referenced-by-count":14,"title":["Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies"],"prefix":"10.1093","volume":"31","author":[{"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Schleswig-Holstein , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IRCCS San Raffaele Hospital and Vita-Salute University , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Lee","sequence":"additional","affiliation":[{"name":"Data Science Institute, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Ju","family":"Bae","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul Gi","family":"Lee","sequence":"additional","affiliation":[{"name":"Data Science Institute, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Data Science Institute, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Data Science Institute, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Science Division, Celltrion, Inc. , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"7","key":"2025102715480310800_CIT0001","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future","volume":"70","author":"D\u2019Haens","year":"2021","journal-title":"Gut."},{"issue":"7","key":"2025102715480310800_CIT0002","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology."},{"issue":"5","key":"2025102715480310800_CIT0003","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2025102715480310800_CIT0004","doi-asserted-by":"publisher","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","article-title":"Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters","volume":"13","author":"Kim","year":"2021","journal-title":"MAbs"},{"issue":"15","key":"2025102715480310800_CIT0005","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3748\/wjg.v30.i15.2068","article-title":"Combination treatment of inflammatory bowel disease: present status and future perspectives","volume":"30","author":"Triantafillidis","year":"2024","journal-title":"World J Gastroenterol."},{"issue":"5","key":"2025102715480310800_CIT0006","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2025102715480310800_CIT0007","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology."},{"issue":"15","key":"2025102715480310800_CIT0008","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"issue":"8","key":"2025102715480310800_CIT0009","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025102715480310800_CIT0010","author":"US Food and Drug Administration","journal-title":"Zymfentra highlights of prescribing information"},{"key":"2025102715480310800_CIT0011","author":"Celltrion, Inc","journal-title":"Celltrion USA announces U.S. FDA approval of ZYMFENTRA\u2122 (infliximab-dyyb), the first and only subcutaneous infliximab, for the treatment of people with inflammatory bowel disease"},{"key":"2025102715480310800_CIT0012","author":"European Medicines Agency","journal-title":"Remsima summary of product characteristics"},{"issue":"5","key":"2025102715480310800_CIT0013","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology."},{"issue":"Supplement_1","key":"2025102715480310800_CIT0014","doi-asserted-by":"publisher","first-page":"i1737","DOI":"10.1093\/ecco-jcc\/jjad212.1087","article-title":"P957: Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study","volume":"18","author":"Sands","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"Suppl_1","key":"2025102715480310800_CIT0015","doi-asserted-by":"publisher","first-page":"i1653","DOI":"10.1093\/ecco-jcc\/jjad212.1032","article-title":"P902: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn\u2019s disease: 2 years results of the LIBERTY-CD study","volume":"18","author":"Colombel","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025102715480310800_CIT0016","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology."},{"issue":"9","key":"2025102715480310800_CIT0017","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2025102715480310800_CIT0018","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial","volume":"43","author":"D\u2019Haens","year":"2023","journal-title":"Clin Drug Investig."},{"issue":"20","key":"2025102715480310800_CIT0019","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA."},{"key":"2025102715480310800_CIT0020","author":"European Medicines Agency","journal-title":"Guideline for good clinical practice E6(R2)"},{"issue":"3","key":"2025102715480310800_CIT0021","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","article-title":"Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn\u2019s disease","volume":"13","author":"Drobne","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2025102715480310800_CIT0022","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut."},{"issue":"1","key":"2025102715480310800_CIT0023","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res"},{"issue":"11","key":"2025102715480310800_CIT0024","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.cgh.2024.04.019","article-title":"Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial","volume":"22","author":"Pudipeddi","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2025102715480310800_CIT0025","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2025102715480310800_CIT0026","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf038\/62928103\/izaf038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2714\/62928103\/izaf038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2714\/62928103\/izaf038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:48:08Z","timestamp":1761594488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/10\/2714\/8098142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,4,30]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf038","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,4,30]]}}}